Five Prime Therapeutics and Second Sight Medical Products are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in the future outlook of their businesses. If a buoyant growth prospect is what you’re after in your next investment, I’ve put together a list of high-growth stocks you may be interested in, based on the latest financial data from each company.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX)
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. Formed in 2001, and headed by CEO Lewis Williams, the company now has 195 employees and with the stock’s market cap sitting at USD $710.48M, it comes under the small-cap category.
FPRX is expected to deliver a buoyant earnings growth over the next couple of years of 28.47%, bolstered by a significant revenue which is expected to more than double. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. Furthermore, the 66.41% growth in operating cash flows indicates that a large portion of this earnings increase is high-quality, day-to-day cash generated by the business, rather than one-offs. FPRX ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Want to know more about FPRX? Have a browse through its key fundamentals here.
Second Sight Medical Products, Inc. (NASDAQ:EYES)
Second Sight Medical Products, Inc. develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the United States, Italy, Germany, France, and Canada. Founded in 1998, and now run by Jonathan McGuire, the company provides employment to 110 people and with the company’s market cap sitting at USD $107.93M, it falls under the small-cap category.
EYES’s forecasted bottom line growth is an optimistic double-digit 27.41%, driven by underlying sales, which is expected to more than double, over the next few years. It appears that EYES’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. EYES’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Thinking of investing in EYES? I recommend researching its fundamentals here.
Cymabay Therapeutics, Inc. (NASDAQ:CBAY)
Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. Founded in 1988, and currently run by Sujal Shah, the company provides employment to 22 people and with the company’s market capitalisation at USD $526.37M, we can put it in the small-cap stocks category.
CBAY’s projected future profit growth is a robust 28.91%, with an underlying 60.58% growth from its revenues expected over the upcoming years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. CBAY ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Thinking of investing in CBAY? Take a look at its other fundamentals here.
For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.